Orismilast - UNION Therapeutics
Alternative Names: IBI-353; LEO32731; LP-0058; UNI-50001; UNI-50002Latest Information Update: 10 Jun 2024
At a glance
- Originator LEO Pharma
- Developer Innovent Biologics; LEO Pharma; UNION Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Benzodioxoles; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyridines; Skin disorder therapies; Small molecules; Spiro compounds
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Ulcerative colitis
Most Recent Events
- 04 Jun 2024 UNION Therapeutics schedules an End of Phase 2 meeting with the US FDA for orismilast development program into phase III trial in Atopic dermatitis
- 04 Jun 2024 UNION therapeutics completes the phase-II ADESOS trial in Atopic dermatitis in Poland, Germany, USA, Hungary (PO) (NCT05469464)
- 04 Jun 2024 UNION therapeutics plans a phase III trial in Atopic dermatitis